Alzheimer's Disease News and Research

RSS

Alzheimer's disease (AD) is an irreversible, progressive brain disease that slowly destroys memory and thinking skills and, eventually, the ability to carry out the simplest tasks of daily living. In most people with AD, symptoms first appear after age 60. AD is the most common cause of dementia among older people, but it is not a normal part of aging. Dementia refers to a decline in cognitive function that interferes with daily life and activities. AD starts in a region of the brain that affects recent memory, then gradually spreads to other parts of the brain. Although treatment can slow the progression of AD and help manage its symptoms in some people, currently there is no cure for this devastating disease.

Pulsed ultrasound used to remote control brain circuits

In a twist on nontraditional uses of ultrasound, a group of neuroscientists at Arizona State University has developed pulsed ultrasound techniques that can remotely stimulate brain circuit activity.

29 Oct 2008

Professor reveals the 'Jennifer Aniston neuron'

According to a top scientist parts of the brain are wired up to be devoted to celebrities.

29 Oct 2008

High-fat diet could promote the development of Alzheimer's

A team of Université Laval researchers has shown that the main neurological markers for Alzheimer's disease are exacerbated in the brains of mice fed a diet rich in animal fat and poor in omega-3s. Details of the study-which suggests that diets typical of most industrialized countries promote the development of Alzheimer's-are outlined in the latest online edition of Neurobiology of Aging.

28 Oct 2008

Selenium and vitamin E supplements do not prevent prostate cancer

Initial, independent review of study data from the Selenium and Vitamin E Cancer Prevention Trial (SELECT), funded by the National Cancer Institute (NCI) and other institutes that comprise the National Institutes of Health shows that selenium and vitamin E supplements, taken either alone or together, did not prevent prostate cancer.

28 Oct 2008

Memory Pharmaceuticals issued key U.S. patent for series of nicotinic alpha-7 receptor agonists

Memory Pharmaceuticals Corp. has announced the issuance of U.S. Patent No. 7,429,664, which provides composition of matter patent protection for a series of nicotinic alpha-7 receptor agonists.

27 Oct 2008

New molecules with many branches will help unleash potential of nanotechnology

Materials science and the pharmaceutical industry could soon be revolutionized by emerging nanotechnologies based on designer molecules with long complex tree-and branch structures. Such molecules offer almost limitless scope for design of bespoke compounds for specific applications in disease therapy, for novel materials such as resins, as well as electronic displays, and energy storage. Almost every field involving design and synthesis of chemical compounds will be transformed by the arrival of technologies allowing nanoscale design of these branched molecules, known as hyperbranched polymers.

26 Oct 2008

Self assembling "organic wires"

From pacemakers constructed of materials that so closely mimic human tissues that a patient's body can't discern the difference to devices that bypass injured spinal cords to restore movement to paralyzed limbs, the possibilities presented by organic electronics read like something from a science fiction novel.

23 Oct 2008

Memory function varies after damage to key area of the brain

Scientists at the University of Liverpool have discovered dramatic differences in the memory performance of patients with damage to the hippocampus, an area of the human brain key to memory.

23 Oct 2008

New obesity drug Tesofensine may have huge potential

According to trials, a new obesity drug, Tesofensine, which may be launched on the world market in a few years, can produce weight loss twice that of currently approved obesity drugs. The Danish company Neurosearch and a number of researchers at the Faculty of Life Sciences at University of Copenhagen are behind the promising findings.

23 Oct 2008

Education and work help beat Alzheimer's

New research has revealed that education and a mentally demanding job protects people from Alzheimer's disease.

22 Oct 2008

Fatty acids may be the culprit in Alzheimer's

According to new research from the U.S. controlling the level of a fatty acid in the brain could help treat Alzheimer's disease (AD).

21 Oct 2008

Johns Hopkins researchers detect sweet cacophany while listening to cellular cross-talk

Johns Hopkins scientists were dubious in the early 1980s when they stumbled on small sugar molecules lurking in the centers of cells; not only were they not supposed to be there, but they certainly weren't supposed to be repeatedly attaching to and detaching from proteins, effectively switching them on and off.

20 Oct 2008

NIH funds two new centers for imaging technology for neurodegenerative disorders and software for protein analysis

The National Center for Research Resources (NCRR), a part of the National Institutes of Health (NIH), announced today it will provide up to an estimated $11 million over the next five years to create two new Biomedical Technology Research Centers (BTRCs) that will provide researchers nationwide with access to specialized research tools, training and state-of-the-art equipment.

15 Oct 2008

Link between dementia and hypotension - Alzheimer's sufferers might have lower blood pressure

A new study published in Bioscience Hypotheses, a recently launched Elsevier journal, proposes that some people suffering from Alzheimer's disease experience a reduction in their high blood pressure because of cognitive decline.

14 Oct 2008

High-dose vitamin B supplements do not slow cognitive decline in Alzheimer's

A clinical trial led by Paul S. Aisen, M.D., professor of neurosciences at the University of California, San Diego School of Medicine, showed that high-dose vitamin B supplements did not slow the rate of cognitive decline in patients with mild to moderate Alzheimer disease.

14 Oct 2008